Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Children born with severe brain-based developmental disabilities frequently experience
persistent unexplained periods of pain and irritability, often compounded by a limited
capacity to communicate their distress. The investigators call this entity Pain and
Irritability of Unknown Origin (PIUO). The rationale of this trial is to identify the
clinical effect size of gabapentin in reducing and resolving pain in children with
developmental brain disorders, specifically those with severe neurological impairment (SNI).
Phase:
Phase 2
Details
Lead Sponsor:
University of British Columbia
Collaborators:
BC Children's Hospital Research Institute Canadian Institutes of Health Research (CIHR) Child-Bright Network